Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Credit Suisse event now available

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Nov 12, 2021 11:53am

84 Views

Post# 34119967

RE:RE:RE:Credit Suisse event now available

Pretty clear at this point they have no capacity to interact with the market in the "modern way" this explains all our issue with the company at this point. The issue is you can hire all the senior ir people you want but if the people making the decisions are unwilling to change then it will be this way for a while

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario